Summary Monoclonal antibody TFS-4 has previously been shown to react selectively with human small cell lung cancer (SCLC). We evaluated the use of 1311-labelled TFS-4 for the treatment of established human SCLC transplanted in nude mice. The specific accumulation of the antibody in the transplanted tumour was recorded by both scintigraphic and biodistribution studies. Administration of 200pCi 131 I-labelled TFS-4 inhibited tumour growth when compared with the same radiation dose of the control monoclonal antibody. The therapeutic effect was dose-dependent and complete disappearance of the tumour was observed transiently in one out of the three animals following the administration of 500 pCi 131 I-labelled TFS-4.
The efficacy of radiotherapy for small cell lung cancer (SCLC) is limited although the tumour cells are usually radiosensitive. This is because SCLC is considered essentially a systemic disease since the tumour rapidly infiltrates over the radiation field and quickly metastasises to distant organs. One possible method for overcoming this situation is the utilisation of a monoclonal antibody as a carrier to deliver radioactive particles to the radiosensitive tumour.
A monoclonal antibody, TFS-4, which specifically reacts with SCLC, has already been developed (Okabe et al., 1984) . It was demonstrated that TFS-4 did not bind to a variety of normal or other malignant cells except for neuroendocrine or APUD cells (Watanabe et al., 1987a, b) . We subsequently studied the use of TFS-4 as an 1311 carrier for the diagnosis of SCLC. Since '311-labelled TFS-4 administered i.v. selectively accumulated in tumour tissue which had been transplanted into a nude mouse, a gamma scintillation camera depicted the clearly-demarcated tumour figure (Okabe & Takaku, 1986) . As beta-emitter, 1311 also has strong destructive power to nearby cells. It was therefore surmised that 131I-labelled TFS-4 could be applied to the treatment of SCLC. This paper reports the antitumour effect of 1311-labelled TFS-4 on human SCLC transplanted in nude mice.
Materials and methods

Monoclonal antibodies
The production of TFS-4 (Okabe et al., 1984) is summarised as follows: hybridoma cells secreting monoclonal antibody TFS-4 were produced by fusion of P3X63Ag8Ul mouse myeloma cells and spleen cells from BALB/c mice immunised against SCLC tumours grown in BALB/c nude mice. TFS-4 is a murine IgGI antibody which recognises the antigen of SCLC cell surface protein with a molecular weight of 124,000 (Okabe et al., 1984; Watanabe et al., 1987b) .
As an irrelevant control antibody, a murine IgGI monoclonal antibody reactive with human recombinant interferon gamma was prepared.
Ascites containing a high-titer monoclonal antibody were produced by injecting hybrid cells (1 x 107) i.p. into BALB/c mice primed with tetramethylpentadecane (Wako Pure Chemical Industries Ltd., Osaka, Japan). The monoclonal antibodies were purified from the ascites by ammonium sulphate precipitation and ion exchange chromatography on Zetaprep-15 DEAE Discs (AMF Ltd.). 
Iodination of monoclonal antibodies
The antibodies were iodinated with 1311 using chloramine-T (Greenwood et al., 1963) . One ml of an antibody (0.5mgml-1 in 10mM PBS, pH7.4) was mixed with 25 il 1311 as sodium iodide (370MBq, Amersham, 10mCi, code IBS 30) and 100 p1 chloramine-T (1 mg ml -1). After incubation for min, 100 Ml Na-metapyrosulphate (2mg ml -1) was added to the solution to stop the reaction. Free iodine was removed by gel filtration using a G-25 Sephadex column equilibrated with PBS containing 0.2% bovine serum albumin. The labelling yield was -40% with a specific activity of 3-7 mCi mg-1.
Animal xenograft models Two human small cell carcinoma cell lines, TNSC-1 (Okabe et al., 1984) and NCI-H69 (Gazdar et al., 1980) , and an adenocarcinoma cell line, HLC-2 (Okabe et al., 1984) were used to produce tumour xenografts in female BALB/c nude mice (4-6 weeks old). TNSC-1 and HLC-2 were established in our laboratory. Cells (3 x 106-3 x 107) were implanted s.c. in the back of a nude mouse. Heterotransplants of nude mouse tumours were histologically and functionally similar to the patients' tumours (Okabe et al., 1984) . Two or three weeks after the inoculation, when diameter of the tumour nodule, being in the exponential growth stage, reached 0.5-1.0 cm, the animal was injected i.p. with a monoclonal antibody solution. Tumour size was measured with calipers every 3-4 days and tumour volume estimated using the following formula Volume = (x/6) x Length x Width2
Scintigraphy and biodistribution Seventy pCi of 1311-labelled TFS-4 was injected i.v. into nude mice 3 weeks after implantation of TNSC-1 cells on both sides of the back of animals. Scintillation imaging was carried out at 1, 2, 4 and 7 days after injection. The mice were anaesthetised by i.p. injection of pentobarbital and attached to boards with adhesive tape. Imaging was obtained externally in a posterior projection using a gamma scintillation camera with a pinhole collimator.
Seven days after i.p. injection of 100,uCi 131I1-labelled TFS-4, the animals were killed and the amount of radioactivity in each organ assessed using a gamma counter. Injection of 300-500uCi led to a significant (P <0.01 by Student's t test) inhibition of tumour growth compared to 0-100pCi.
Results
Antibody localisation
Twenty-four hours after injection of 131I-labelled TFS-4, gamma scintigraphy showed whole-mouse figures without tumour contours. Four days after injection, the tumours were clearly imaged. On day 7, tumours were even more clearly demarcated, with decreased background radioactivity (Figure 1) .
Specific accumulation of radioactivity in the tumour tissue was also demonstrated by biodistribution. Figure 2 the distribution of radioactivity in 4 animals on day 7 after injection of 131I-labelled TFS-4. The concentration of radioactivity in the tumour tissue (TNSC-1) was higher than that in the normal tissues. The tumour-to-blood radioactivity ratio was 4.33 + 1.60 (mean + s.e.). The ratios of the tumour to the normal tissues other than blood were > 8: 1. Radioactivity in the brain was extremely low probably due to the blood-brain barrier. When 13 11-labelled anti-gamma interferon antibody, which is not specific to SCLC, was injected as a control, radioactivity levels in the tumour and normal tissues were closely similar.
Effect on SCLC Dose dependency of the therapeutic effect of 131I-labelled TFS-4 on SCLC xenografts in nude mice is shown in Figure  3 . Groups of 3 animals with TNSC-1 nodules of -0.5-1.0cm in diameter were injected with varying doses of 1311.
labelled TFS-4. The original tumour sizes were equal between the groups. Animals were observed over a 16-day period. Injection of 300-500,yCi 131I-labelled TFS-4 led to a marked inhibition of tumour growth compared to 0-)100pCi 1311-labelled TFS-4. The mean volume of tumours treated with 500pCi 1311-labelled TFS-4 decreased to -60% of the original, and the s.c. nodule disappeared transiently in one of the three animals. Figure 4 shows the effect of 200,uCi 131I-labelled TFS-4 on TNSC-1 in comparison to the two controls, i.e., the same radiation dose of the control monoclonal antibody, and the same protein dose of unlabelled TFS-4. It is clear that tumour growth was inhibited by 131I-labelled TFS-4.
Effect on various lung cancers The antitumour effect of 200 pCi 1311I-labelled TFS-4 was examined in three different lung cancers: two SCLCs (TNSC-1 and NCI-H69) and an adenocarcinoma (HLC-2) Repeated injection 131I-labelled TFS-4 (500pCi) was injected twice into animals bearing TNSC-1 nodules with a 5-week interval. The tumour volume was measured over a 79-day period; from initial injection to the regrowth of tumour nodules. As is shown in Figure 6 , the second injection was as effective as the first with tumour regression persisting for 14 days after each injection although the nodules began to regrow thereafter, in contrast to the rapid and steady growth of the untreated nodules.
Discussion
Monoclonal antibodies offer a high potential for use in the treatment as well as diagnosis of cancer. One of the most promising applications is in a treatment strategy in which a cytocidal radioisotope is conjugated with tumour-specific monoclonal antibody.
Badger et al. (1985) studied a 131I-labelled monoclonal antibody for treating established murine lymphoma. At a dose of 500 pCi, tumour nodules regressed in 44% of the animals. Cheung et al. Jones et al. (1985) reported tumoricidal effects of a 131I-labelled monoclonal antibody in nude mice xenografted with human neuroblastoma. Wakabayashi et al. (1984) clarified the antitumour effects of 1311-labelled monoclonal antibodies in mice transplanted with murine melanoma. Clinically, Rosen et al. (1987) (Figure 3) . Although mCi of the antibody seemed to be more effective, it resulted in a higher death rate probably because of increased toxicity. The antitumour effect appears to be achieved not only by high radiosensitivity of the tumour, but also by the specific accumulation of 1311_ labelled TFS-4 in tumour tissues shown by scintigraphy-in Figure 1 and by biodistribution in Figure 2 . On the basis of scintigram the tumour-absorbed dose from the 131I was calculated to be 10.38 Gy, i.e., 9.99 Gy by ,B beam and 0.39Gy by y beam. Unlabelled TFS-4 did not inhibit the growth of SCLC xenografts (Figure 4) . A murine IgGI monoclonal antibody to human interferon, which was radiolabelled with 1311, did not accumulate specifically into the SCLC xenografts. Tumour growth was not inhibited by the 1311-labelled anti-interferon antibody. Although radiolabelled TFS-4 inhibited tumour growth in two small-cell carcinomas, it was ineffective against the adenocarcinoma of the lung (Figure 5 ), which has previously been shown to be unreactive with (Okabe et al., 1984; Watanabe et al., 1987a 
